Literature DB >> 29549905

The impact of acute inflammation on progression and metastasis in pancreatic cancer animal model.

Keun Soo Ahn1, Ji Yeon Hwang2, Ho-Seong Han3, Sang Tae Kim4, Ilseon Hwang5, Young-Ok Chun2.   

Abstract

BACKGROUND: The impact of acute inflammation on cancer is unclear. Therefore, we evaluated the impact of acute inflammation on cancer progression in an animal model concerning morphological change as well as molecular features.
MATERIAL AND METHODS: Murine pancreas ductal adenocarcinoma cell line (Panc-02) and zymosan were used for the induction of cancer and acute inflammation respectively, in C57/BL6 mice. In the C group (n = 10), 2 × 107Panc02 cells were injected into the tail of the pancreas. In the Z1 (n = 10) and Z2 (n = 10), 3 mg of zymosan was injected intraperitoneally once and twice respectively, after tumor cell injection. All of the mice were sacrificed 4 weeks after tumor cell injection.
RESULTS: The degree of inflammation was more severe in the Z2 group than in the other two groups. The tumor volume of the Z2 group was larger than that of the C group (P = 0.032) and the presence of liver metastasis was significantly more common in the Z2 group than in the C and Z1 groups (P = 0.025). Confocal microscopy analysis revealed significantly more expression of Snail, EpCAM, Muc1, NLRP3 and miR-155 in the liver and pancreas in the Z2 group than in the other two groups. EpCAM and Muc1 were detected in blood samples in the Z2 group by flow cytometry, but not in the other two groups. In the Z2, expression of E-Cadherin was weaker and vimentin, snail1 were stronger compared to the C and Z1 group in the PCR and western blot.
CONCLUSION: Present results suggest that acute inflammation accompanied with cancer promotes cancer progression by the epithelial-to-mesenchymal transition (EMT) and circulating tumor cells (CTC) process.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute inflammation; Cancer; Circulating tumor cell; Epithelial-to-mesenchymal transition

Mesh:

Substances:

Year:  2017        PMID: 29549905     DOI: 10.1016/j.suronc.2017.11.008

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  6 in total

1.  Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma.

Authors:  Asmita Chopra; Ruben Zamora; Yoram Vodovotz; Jacob C Hodges; Derek Barclay; Randall Brand; Richard L Simmons; Kenneth K Lee; Alessandro Paniccia; Pranav Murthy; Michael T Lotze; Brian A Boone; Amer H Zureikat
Journal:  J Immunother       Date:  2021-06-01       Impact factor: 4.912

Review 2.  Cell-in-Cell Phenomenon and Its Relationship With Tumor Microenvironment and Tumor Progression: A Review.

Authors:  Xinlong Wang; Yilong Li; Jiating Li; Le Li; Hong Zhu; Hua Chen; Rui Kong; Gang Wang; Yongwei Wang; Jisheng Hu; Bei Sun
Journal:  Front Cell Dev Biol       Date:  2019-12-03

3.  Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis.

Authors:  Xing Li; Lijiang Gu; Yuhang Chen; Yue Chong; Xinyang Wang; Peng Guo; Dalin He
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 4.  Advances in the Biology, Detection Techniques, and Clinical Applications of Circulating Tumor Cells.

Authors:  Siwen Wu; Shubi Zhao; Dawei Cui; Jue Xie
Journal:  J Oncol       Date:  2022-09-02       Impact factor: 4.501

Review 5.  Tackling Surgical Morbidity and Mortality through Modifiable Risk Factors in Cancer Patients.

Authors:  Boram Lee; Ho-Seong Han
Journal:  Nutrients       Date:  2022-07-28       Impact factor: 6.706

6.  Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes.

Authors:  Thomas M Pausch; Elisa Aue; Naita M Wirsik; Aida Freire Valls; Ying Shen; Praveen Radhakrishnan; Thilo Hackert; Martin Schneider; Thomas Schmidt
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.